Use of metallic cations to improve functional activity of antibodies

Details for Australian Patent Application No. 2004283925 (hide)

Owner Laboratoire Francais du Fractionnement et des Biotechnologies

Inventors Ducancel, Frederic; Stura, Enrico; Glacet, Arnaud; Teillaud, Jean-Luc; Bourel, Dominique; Jorieux, Sylvie

Agent Davies Collison Cave

Pub. Number AU-A-2004283925

PCT Pub. Number WO2005/040216

Priority 0312228 20.10.03 FR

Filing date 20 October 2004

Wipo publication date 6 May 2005

International Classifications

C07K 16/00 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 16/34 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Event Publications

11 May 2006 PCT application entered the National Phase

  PCT publication WO2005/040216 Priority application(s): WO2005/040216

15 January 2009 Assignment before Grant

  Laboratoire Francais du Fractionnement et des Biotechnologies The application has been assigned to LFB Biotechnologies

17 May 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004283926-Method for partial or total oxidation of one or several thiocarbonylthio ends of a polymer obtained by radical polymerisation controlled by reversible additioncleavage

2004283924-Correlation between the fucose content / galactose content ratio of antirhesus-D and anti-HLA-DR antibodies and the ADCC activity